July 10, 2019
The Ministry of Health, Labor and Welfare (MHLW) on July 9 ordered label revisions related to adverse reactions for a batch of drugs including the anti-PD-1 antibodies Opdivo (nivolumab) and Keytruda (pembrolizumab) and Pfizer’s breast cancer drug Ibrance (palbociclib). In...read more